Amyloid Formation

Amyloid Formation describes the pathological process by which normally soluble proteins misfold and aggregate into insoluble fibrillar structures with characteristic cross-beta sheet architecture, accumulating in tissues and causing cellular dysfunction in neurodegenerative diseases, diabetes, and systemic amyloidoses. These ordered protein aggregates exhibit distinctive Congo red staining with apple-green birefringence.

The biopharmaceutical industry focuses on amyloid formation as both a therapeutic target in neurodegeneration and a formulation concern for protein therapeutics. Drug development for Alzheimer's disease, Parkinson's disease, and transthyretin amyloidosis employs small molecules, antibodies, and RNA therapeutics preventing amyloid formation or clearing existing aggregates. Biologic formulation must avoid conditions promoting amyloid-like aggregation. Analytical characterisation employs thioflavin T fluorescence, electron microscopy, and solid-state NMR characterising fibrillar properties. As understanding deepens regarding nucleation mechanisms, therapeutic strategies increasingly target early oligomeric species preceding mature fibril formation.